Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Melinta Therapeutics LLC
Headquarters: New Haven, CT, United States of America
Website: http://www.melinta.com
Year Founded: 2000
Status: Private
BioCentury | Nov 20, 2024
Product Development
Biotechs now match pharma for FDA approvals
Half of FDA approvals are sponsored by biotechs; almost all are marketing in the U.S. themselves
BioCentury | Sep 5, 2024
Management Tracks
Pfizer names Elif Aral president of MERA
Plus: CEO Amy Emerson steps down at Lykos, David Hough made CMO, and updates from Opthea, Modus, Melinta and more
BioCentury | Dec 23, 2023
Regulation
Dec. 22 Quick Takes: Sarepta seeking expanded label, full approval of DMD gene therapy
Plus: June PDUFA date for Daiichi-Merck ADC, and updates from Lyndra, ImpriMed, Mundipharma and Novamab
BioCentury | Mar 22, 2023
Finance
March 22 Quick Takes: GordonMD, Pfizer Ventures lead Flare’s $123M B round
Plus: FDA approvals for Cidara, Incyte and updates from Karuna, Astellas, NImmune, AbbVie, Roche, Lilly
BioCentury | Feb 14, 2023
Market Access
How a narrow FDA label could smooth rezafungin’s launch
Cidara’s antifungal has backing of FDA panel for a limited use indication that homes in on the unmet need
BioCentury | Jan 25, 2023
Regulation
Jan. 24 Quick Takes: FDA panel backs Cidara’s rezafungin
Plus: Amid IP issues, Finch sheds staff and updates from CymaBay, Allogene, Lilly
BioCentury | Jan 21, 2023
Finance
Jan. 20 Quick Takes: Moderna vets pick ADARx for new VC’s debut investment
Plus: Clinical hold lifted on Astellas gene therapy, FDA reviewers scrutinize rezafungin’s benefit and updates from Deciphera, Disc and more
BioCentury | Jul 28, 2022
Regulation
July 27 Quick Takes: Cidara, Melinta in deal for antifungal headed to FDA
Plus Legend gains after upsizing financing and updates from Lexicon, ObsEva, Cassava, Legend and more
BioCentury | Jun 29, 2021
Management Tracks
Ogilvy’s Cronin joins Moderna; plus Gates Foundation, Turning Point, Quanterix, Esperion, Eikon and more
Kate Cronin will join Moderna Inc. (NASDAQ:MRNA) as chief brand officer on July 12. Cronin was global CEO at Ogilvy Health, a part of WPP plc (NYSE:WPP). Emilio Emini will become interim CEO of the
BioCentury | Apr 2, 2021
Management Tracks
BeiGene unveils new CFO; plus Precigen, Alphamab, Flagship, Melinta, Immunome and more
BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) promoted SVP Julia Wang to CFO, effective June 30. Wang, who joined BeiGene last June, has held leadership roles in finance at Alexion Pharmaceuticals Inc.
Items per page:
1 - 10 of 10